{"transactions":[{"id":752342,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-06-04T00:03:06.000Z","date":"2026-06-02","kind":"grant","planned":true,"acquired":true,"shares":15673,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15673,"derivative":{"exercise_price":19.82,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":15673},"source":{"system":"sec-edgar","filing":"0001347383-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134738326000003/primarydocument.xml","form_type":"4"}},{"id":752341,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-04T00:03:06.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":600,"price":21.38,"value":12828.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":17609,"source":{"system":"sec-edgar","filing":"0001347383-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134738326000003/primarydocument.xml","form_type":"4"}},{"id":752340,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-04T00:03:06.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":5456,"price":20.21,"value":110265.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":18209,"source":{"system":"sec-edgar","filing":"0001347383-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134738326000003/primarydocument.xml","form_type":"4"}},{"id":1002274,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-11-12T21:17:36.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":51588,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6056},"source":{"system":"sec-edgar","filing":"0001347383-25-000009","document":"form4-11122025_091132.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134738325000009/form4-11122025_091132.xml","form_type":"4"}},{"id":1002273,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:17:36.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":6056,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."}],"balance_after":23665,"source":{"system":"sec-edgar","filing":"0001347383-25-000009","document":"form4-11122025_091132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134738325000009/form4-11122025_091132.xml","form_type":"4"}},{"id":1005022,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-07T21:15:18.000Z","date":"2025-11-05","kind":"grant","planned":false,"acquired":true,"shares":37960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One third (1/3) of the shares subject to the option award shall vest on November 5, 2026 and the remaining shares subject to the option shall vest in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":37960,"derivative":{"exercise_price":16,"expiration_date":"2035-11-04","underlying":"Common Stock","underlying_shares":37960},"source":{"system":"sec-edgar","filing":"0001347383-25-000007","document":"form4-11072025_041114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134738325000007/form4-11072025_041114.xml","form_type":"4"}},{"id":1917941,"issuer":{"id":110330,"kind":"organization","name":"Timber Pharmaceuticals, Inc.","symbol":"TMBR"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-04-18T15:32:08.000Z","date":"2023-04-15","kind":"grant","planned":false,"acquired":true,"shares":4100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the options vest on April 15, 2024, and the remaining shares will become exercisable in 36 equal monthly installments beginning on May 15, 2024, as long as the Reporting Person remains in continuous service with Timber Pharmaceuticals, Inc. through each vesting date."}],"balance_after":4100,"derivative":{"exercise_price":1.66,"expiration_date":"2032-04-14","underlying":"Common Stock","underlying_shares":4100},"source":{"system":"sec-edgar","filing":"0001437749-23-010513","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000143774923010513/rdgdoc.xml","form_type":"4"}},{"id":1917940,"issuer":{"id":110330,"kind":"organization","name":"Timber Pharmaceuticals, Inc.","symbol":"TMBR"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true}}],"security":"Common Stock, par value $0.001 per share","published_at":"2023-04-18T15:32:08.000Z","date":"2023-04-15","kind":"grant","planned":false,"acquired":true,"shares":4100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 15, 2023, the Reporting Person was granted 4,100 restricted stock units, which will be settled in shares of common stock, par value $0.001. The restricted stock units vest in 12 equal monthly installments beginning on May 15, 2023, as long as the Reporting Person remains in continuous service with Timber Pharmaceuticals, Inc. through each vesting date."}],"balance_after":6100,"source":{"system":"sec-edgar","filing":"0001437749-23-010513","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000143774923010513/rdgdoc.xml","form_type":"4"}},{"id":2294574,"issuer":{"id":110330,"kind":"organization","name":"Timber Pharmaceuticals, Inc.","symbol":"TMBR"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-19T16:59:52.000Z","date":"2022-04-15","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the options vest on April 15, 2023, and the remaining shares will become exercisable in 24 equal monthly installments beginning on May 15, 2023, as long as the Reporting Person remains in continuous service with the Issuer through each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":0.307,"expiration_date":"2032-04-14","underlying":"Common Stock, par value $0.001 per share","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-22-047218","document":"tm2212708-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000110465922047218/tm2212708-5_4seq1.xml","form_type":"4"}},{"id":2294573,"issuer":{"id":110330,"kind":"organization","name":"Timber Pharmaceuticals, Inc.","symbol":"TMBR"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2022-04-19T16:59:52.000Z","date":"2022-04-15","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 15, 2022, the Reporting Person was granted 100,000 restricted stock units, which will be settled in shares of common stock, par value $0.001, of Timber Pharmaceuticals, Inc. (the \"Issuer\"). The restricted stock units vest in 12 equal monthly installments beginning on May 15, 2022, as long as the Reporting Person remains in continuous service with the Issuer through each vesting date."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001104659-22-047218","document":"tm2212708-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000110465922047218/tm2212708-5_4seq1.xml","form_type":"4"}},{"id":2519328,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T22:37:34.000Z","date":"2021-11-09","kind":"disposition_to_issuer","acquired":false,"shares":96975,"price":5.92,"value":574092.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the payment per share of Common Stock received in exchange for the cancellation of each Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options (\"Options\") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option."}],"balance_after":0,"derivative":{"exercise_price":3.58,"expiration_date":"2031-05-12","underlying":"Common Stock, par value $0.001","underlying_shares":96975},"source":{"system":"sec-edgar","filing":"0001104659-21-136401","document":"tm2131118-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000110465921136401/tm2131118-4_4seq1.xml","form_type":"4"}},{"id":2519327,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T22:37:34.000Z","date":"2021-11-09","kind":"disposition_to_issuer","acquired":false,"shares":85034,"price":5.06,"value":430272.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the payment per share of Common Stock received in exchange for the cancellation of each Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options (\"Options\") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option."}],"balance_after":0,"derivative":{"exercise_price":4.44,"expiration_date":"2030-05-13","underlying":"Common Stock, par value $0.001","underlying_shares":85034},"source":{"system":"sec-edgar","filing":"0001104659-21-136401","document":"tm2131118-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000110465921136401/tm2131118-4_4seq1.xml","form_type":"4"}},{"id":2519326,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T22:37:34.000Z","date":"2021-11-09","kind":"disposition_to_issuer","acquired":false,"shares":100000,"price":7.21,"value":721000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the payment per share of Common Stock received in exchange for the cancellation of each Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options (\"Options\") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option."}],"balance_after":0,"derivative":{"exercise_price":2.29,"expiration_date":"2029-05-15","underlying":"Common Stock, par value $0.001","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-21-136401","document":"tm2131118-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000110465921136401/tm2131118-4_4seq1.xml","form_type":"4"}},{"id":2519325,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T22:37:34.000Z","date":"2021-11-09","kind":"disposition_to_issuer","acquired":false,"shares":64935,"price":7.23,"value":469480.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the payment per share of Common Stock received in exchange for the cancellation of each Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options (\"Options\") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option."}],"balance_after":0,"derivative":{"exercise_price":2.27,"expiration_date":"2029-02-06","underlying":"Common Stock, par value $0.001","underlying_shares":64935},"source":{"system":"sec-edgar","filing":"0001104659-21-136401","document":"tm2131118-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000110465921136401/tm2131118-4_4seq1.xml","form_type":"4"}},{"id":2640726,"issuer":{"id":110330,"kind":"organization","name":"Timber Pharmaceuticals, Inc.","symbol":"TMBR"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-06T20:06:16.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":71893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the compensation committee of the board of directors of Timber Pharmaceuticals, Inc. (the \"Company\") on April 21, 2021, subject to stockholder approval of an amendment to the Company's 2020 Omnibus Equity Incentive Plan (the \"Amendment\"). The Company's stockholders approved the Amendment on July 1, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option grant will vest in 24 equal monthly installments beginning on August 1, 2021."}],"balance_after":71893,"derivative":{"exercise_price":1.18,"expiration_date":"2031-07-01","underlying":"Common Stock, par value $0.001 per share","underlying_shares":71893},"source":{"system":"sec-edgar","filing":"0001104659-21-089394","document":"tm2121501-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000110465921089394/tm2121501-1_4.xml","form_type":"4"}},{"id":2714135,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-13T20:10:39.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":96975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the first anniversary of the grant date, or May 12, 2022"}],"balance_after":96975,"derivative":{"exercise_price":3.58,"expiration_date":"2031-05-12","underlying":"Common stock","underlying_shares":96975},"source":{"system":"sec-edgar","filing":"0001593968-21-001311","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000159396821001311/primary_01.xml","form_type":"4"}},{"id":3148580,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-14T20:24:31.000Z","date":"2020-05-13","kind":"grant","acquired":true,"shares":85034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option becomes vested and exercisable on May 13, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Only represents derivative securities of this class."}],"balance_after":85034,"derivative":{"exercise_price":4.44,"exercise_date":"2021-05-13","expiration_date":"2030-05-13","underlying":"Common stock, $0.001 par value","underlying_shares":85034},"source":{"system":"sec-edgar","filing":"0001593968-20-001174","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000159396820001174/primary_01.xml","form_type":"4"}},{"id":3252435,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-02-25T00:31:37.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-20-001614","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218020001614/primarydocument.xml","form_type":"4"}},{"id":3252434,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-25T00:31:37.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.38,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001614","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218020001614/primarydocument.xml","form_type":"4"}},{"id":3252433,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-25T00:31:37.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.95,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001614","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218020001614/primarydocument.xml","form_type":"4"}},{"id":3252432,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-25T00:31:37.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.01,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001614","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218020001614/primarydocument.xml","form_type":"4"}},{"id":3252431,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-25T00:31:37.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":10344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.82,"expiration_date":"2026-06-20","underlying":"Common Stock","underlying_shares":10344},"source":{"system":"sec-edgar","filing":"0001562180-20-001614","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218020001614/primarydocument.xml","form_type":"4"}},{"id":3252430,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-25T00:31:37.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":10344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2025-06-10","underlying":"Common Stock","underlying_shares":10344},"source":{"system":"sec-edgar","filing":"0001562180-20-001614","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218020001614/primarydocument.xml","form_type":"4"}},{"id":3252429,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-25T00:31:37.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":14224,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":5.51,"expiration_date":"2024-06-05","underlying":"Common Stock","underlying_shares":14224},"source":{"system":"sec-edgar","filing":"0001562180-20-001614","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218020001614/primarydocument.xml","form_type":"4"}},{"id":3252428,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Stock Option (Right to buy)","published_at":"2020-02-25T00:31:37.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":8620,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0.986,"expiration_date":"2021-10-03","underlying":"Common Stock","underlying_shares":8620},"source":{"system":"sec-edgar","filing":"0001562180-20-001614","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218020001614/primarydocument.xml","form_type":"4"}},{"id":3252427,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Stock Option (Right to buy)","published_at":"2020-02-25T00:31:37.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":17241,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0.986,"expiration_date":"2021-10-03","underlying":"Common Stock","underlying_shares":17241},"source":{"system":"sec-edgar","filing":"0001562180-20-001614","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218020001614/primarydocument.xml","form_type":"4"}},{"id":3252426,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-25T00:31:37.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":35682,"price":18.75,"value":669037.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-20-001614","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218020001614/primarydocument.xml","form_type":"4"}},{"id":3489303,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:16:44.000Z","date":"2019-06-12","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU, which was granted on June 12, 2018, fully vested on June 12, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-19-003533","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218019003533/primarydocument.xml","form_type":"4"}},{"id":3489302,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:16:44.000Z","date":"2019-06-12","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":35682,"source":{"system":"sec-edgar","filing":"0001562180-19-003533","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218019003533/primarydocument.xml","form_type":"4"}},{"id":3498531,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2019-06-07T00:15:20.000Z","date":"2019-06-04","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU will vest 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-19-003403","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218019003403/primarydocument.xml","form_type":"4"}},{"id":3498530,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-06-07T00:15:20.000Z","date":"2019-06-04","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest and become exercisable as to 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":9.38,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-19-003403","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218019003403/primarydocument.xml","form_type":"4"}},{"id":3523295,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-16T20:53:37.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":100000,"price":2.29,"value":229000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option becomes vested and exercisable on May 15, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Only represents derivative securities of this class."}],"balance_after":164935,"derivative":{"exercise_price":2.29,"exercise_date":"2020-05-15","expiration_date":"2029-05-15","underlying":"Common stock, par value $0.001","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001593968-19-001126","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000159396819001126/primary_01.xml","form_type":"4"}},{"id":3670117,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2019-02-07T21:24:51.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":64935,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes vested and exercisable in three equal annual installments over 3 years from February 6, 2019, the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Only represents derivative securities of this class."}],"balance_after":64935,"derivative":{"exercise_price":2.27,"expiration_date":"2029-02-06","underlying":"Common Stock, par value $0.001","underlying_shares":64935},"source":{"system":"sec-edgar","filing":"0001593968-19-000374","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000159396819000374/primary_01.xml","form_type":"4"}},{"id":3893532,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2018-06-14T21:45:43.000Z","date":"2018-06-13","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSU, which was granted on June 13, 2017, fully vested on June 13, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-18-003003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218018003003/primarydocument.xml","form_type":"4"}},{"id":3893531,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2018-06-14T21:45:43.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSU will vest 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-18-003003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218018003003/primarydocument.xml","form_type":"4"}},{"id":3893530,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-14T21:45:43.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest and become exercisable as to 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":9.95,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-18-003003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218018003003/primarydocument.xml","form_type":"4"}},{"id":3893529,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-14T21:45:43.000Z","date":"2018-06-13","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired upon vesting of RSU granted on June 13, 2017."}],"balance_after":32682,"source":{"system":"sec-edgar","filing":"0001562180-18-003003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218018003003/primarydocument.xml","form_type":"4"}},{"id":4019398,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-02T21:25:36.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":600,"price":25.85,"value":15510.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":29682,"source":{"system":"sec-edgar","filing":"0001562180-18-001392","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218018001392/primarydocument.xml","form_type":"4"}},{"id":4078709,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-02T21:46:02.000Z","date":"2018-02-01","kind":"sale","acquired":false,"shares":600,"price":28.87,"value":17322.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $28.85 to $28.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":30282,"source":{"system":"sec-edgar","filing":"0001562180-18-000590","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218018000590/primarydocument.xml","form_type":"4"}},{"id":4106909,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-04T21:15:55.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":600,"price":28.03,"value":16818.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":30882,"source":{"system":"sec-edgar","filing":"0001562180-18-000200","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218018000200/primarydocument.xml","form_type":"4"}},{"id":4141594,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-05T21:00:36.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":600,"price":25.49,"value":15294.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":31482,"source":{"system":"sec-edgar","filing":"0001562180-17-003741","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218017003741/primarydocument.xml","form_type":"4"}},{"id":4172478,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-03T21:19:29.000Z","date":"2017-11-01","kind":"sale","acquired":false,"shares":600,"price":26.82,"value":16092.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":32082,"source":{"system":"sec-edgar","filing":"0001562180-17-003468","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218017003468/primarydocument.xml","form_type":"4"}},{"id":4193939,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-03T20:02:33.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":600,"price":26.99,"value":16194.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":32682,"source":{"system":"sec-edgar","filing":"0001562180-17-003164","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218017003164/primarydocument.xml","form_type":"4"}},{"id":4217601,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-05T20:46:44.000Z","date":"2017-09-01","kind":"sale","acquired":false,"shares":600,"price":23.56,"value":14136.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":33282,"source":{"system":"sec-edgar","filing":"0001562180-17-002835","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218017002835/primarydocument.xml","form_type":"4"}},{"id":4222333,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-29T23:12:47.000Z","date":"2017-08-28","kind":"sale","acquired":false,"shares":600,"price":23.81,"value":14286.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."}],"balance_after":33882,"source":{"system":"sec-edgar","filing":"0001562180-17-002803","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218017002803/primarydocument.xml","form_type":"4"}},{"id":4280432,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2017-06-15T21:11:31.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU will vest 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-17-002276","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218017002276/primarydocument.xml","form_type":"4"}},{"id":4280431,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-06-15T21:11:31.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest and become exercisable as to 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":28.01,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-17-002276","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347383/000156218017002276/primarydocument.xml","form_type":"4"}}]}